SuperworthAcadia Pharmaceuticals EPS ACAD
Diluted earnings per share by quarter and over the last twelve months, from 2010.
- Last 12 months, to Jun 30, 2026
- $2.21
- Latest quarter, Q2 FY26
- $0.18
- +13% on a year earlier
- Fiscal year 2025
- $2.28
- +68% on the year before
Acadia Pharmaceuticals' earnings per share was $2.21 over the twelve months to Jun 30, 2026, up 66% on a year earlier.
In its latest quarter, Q2 FY26, it was $0.18, up 12% on the same quarter a year before.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $2.28 | +68% |
| FY2024 | $1.36 | n/a |
| FY2023 | −$0.38 | n/a |
| FY2022 | −$1.34 | n/a |
| FY2021 | −$1.05 | n/a |
| FY2019 | −$1.60 | n/a |
| FY2018 | −$1.95 | n/a |
| FY2017 | −$2.35 | n/a |
| FY2016 | −$2.34 | n/a |
| FY2015 | −$1.63 | n/a |
| FY2014 | −$0.94 | n/a |
| FY2013 | −$0.44 | n/a |
| FY2012 | −$0.37 | n/a |
| FY2011 | −$0.44 | n/a |
| FY2010 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $0.18 | +13% | $2.21 | |
| Q1 FY26 | $0.02 | −82% | $2.19 | |
| Q4 FY25 | $1.59 | +85% | $2.28 | |
| Q3 FY25 | $0.42 | +110% | $1.55 | |
| Q2 FY25 | $0.16 | −20% | $1.33 | |
| Q1 FY25 | $0.11 | +10% | $1.37 | |
| Q4 FY24 | $0.86 | +207% | $1.36 | |
| Q3 FY24 | $0.20 | n/a | $0.78 | |
| Q2 FY24 | $0.20 | +1900% | $0.18 | |
| Q1 FY24 | $0.10 | n/a | −$0.01 | |
| Q4 FY23 | $0.28 | n/a | −$0.38 | |
| Q3 FY23 | −$0.40 | n/a | −$0.92 |
Against its peers
Companies in Drug Manufacturers - General nearest Acadia Pharmaceuticals' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| ACADAcadia Pharmaceuticals | $2.21 | +66% a year |
| OGNOrganon | $0.77 | −71% a year |
| LQDALiquidia | $1.39 | |
| ARQTArcutis Biotherapeutics | $0.22 | |
| INDVIndivior Pharmaceuticals | $2.78 | +227% a year |
| NRIXNurix Therapeutics | $2.31 | |
| PBHPrestige Consumer Healthcare | $3.57 | −16% a year |
| HRMYHarmony Biosciences | $3.09 | −0% a year |
| KNSAKiniksa Pharmaceuticals International | $0.97 | +2325% a year |
| LGNDLigand Pharmaceuticals | $9.40 | |
| AMRXAmneal Pharmaceuticals | $0.49 | +4800% a year |
| Peer median | $1.85 |
Where Acadia Pharmaceuticals ranks
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Acadia Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.